Clinical Characterization Protocol for Severe Emerging Infections
The University of Nebraska Medical Center and Nebraska Medicine established its variation of the Clinical Characterization Protocol for Severe Emerging Infections during the COVID-19 pandemic. CCPSEI is a prospective, observational cohort study that enrolls suspected and confirmed cases of high consequence pathogens, such as pandemic-threat disease, those listed on the U.S. Select Agent list, and other emerging and re-emerging threats that are particularly problematic for patients and communities.The protocol was adapted from the harmonized clinical trial efforts of the International Severe Acute Respiratory and emerging Infection Consortium.
CCPSEI is approved by the UNMC | NM Institutional Review Board, protocol number 146-20-FB, and has been adopted by other centers both through the central IRB mechanism for the Special Pathogen Research Network as well as independently. Learn more with this brief description of the study and its initiation.
Download the Landscape Attribution-ShareAlike 4.0 International
This website is established in support of the open data movement, with the belief that data transparency enables discovery, better clinical and public health practice, and discourse on improving outcomes in risk management of such threats.
Disclaimer Acknowledgement
The Limited Data Set is provided by UNMC’s CCPSEI BioBank AS IS WITHOUT ANY WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE. The User understands and agrees that he/she/it will bear any and all liabilities arising from his/her/its use of the Limited Data Set. The User also understands and agrees that he/she/it will comply with the version of the Creative Commons license set forth on the next page.
I acknowledge the above disclaimer (View PDF).
M. Jana Broadhurst, MD, PhD, DTMH
Scholar, Global Center for Health Security
Assistant Professor, Department of Pathology, Microbiology and Immunology UNMC College of Medicine